Adage Capital Partners Gp, L.L.C. Syndax Pharmaceuticals Inc Transaction History
Adage Capital Partners Gp, L.L.C.
- $56.4 Billion
- Q2 2025
A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 1,432,440 shares of SNDX stock, worth $23.2 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
1,432,440
Previous 631,640
126.78%
Holding current value
$23.2 Million
Previous $7.76 Million
72.91%
% of portfolio
0.02%
Previous 0.02%
Shares
24 transactions
Others Institutions Holding SNDX
# of Institutions
248Shares Held
100MCall Options Held
1.28MPut Options Held
1.29M-
Kynam Capital Management, LP Princeton, NJ8.52MShares$138 Million9.53% of portfolio
-
Black Rock Inc. New York, NY7.91MShares$128 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY5.8MShares$93.9 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.03MShares$81.5 Million0.0% of portfolio
-
Eversept Partners, LP New York, NY4.07MShares$65.8 Million3.84% of portfolio
About Syndax Pharmaceuticals Inc
- Ticker SNDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,565,200
- Market Cap $916M
- Description
- Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...